Navigation Links
Complete revascularization improves outcomes for CAD patients
Date:4/23/2010

A 3-year, retrospective study by cardiologists from the Minneapolis Heart Institute Foundation and the University of Minnesota determined that 28.8% of patients with significant coronary artery disease (CAD) who did not undergo complete revascularization had a higher mortality rate than patients completely revascularized. Results of this study appear in the May issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

The research team led by Timothy Henry, M.D., FSCAI, reviewed angiographs and clinical data from 493 patients treated at the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis, between July 2005 and August 2005. Patients were categorized based on angiographic results and initial treatment: (1) normal coronaries, (2) CAD <70%, (3) CAD >70% with complete revascularization (CR) by PCI or CABG, (4) CAD >70% with partial revascularization (PR) by PCI or CABG, (5) CAD >70% without revascularization treated with medical therapy, and (6) CAD >70% with no revascularization options despite optimal medical therapy. PCI or percutaneous coronary intervention is commonly known as angioplasty and is a common intervention used to treat CAD. CABG or coronary artery bypass grafting is another procedure where blood vessels from another part of the body (the graft) are transplanted to reroute blood around the blocked artery.

In the current study, the research team determined the prevalence of treatment options for groups 1-6 (noted above) was 14.8%, 19.5%, 36.9%, 12.8%, 9.3% and 6.7%, respectively. Researchers also found that 3-year mortality increased with angiographic severity of CAD with groups 1-6 having a 2.7%, 6.3%, 8.2%, 12.7%, 17.4%, and 15.2%, rate respectively. "Our results showed patients with incomplete revascularization (groups 4-6) had a risk of mortality more than double that of completely revascularized patients," said Dr. Henry. After 3 years, study participants with incomplete revascularization had a 14.8% mortality risk compared with 6.6% in patients with complete revascularization.

Additionally, the team found that patients with incomplete revascularization were older, more often male, and more likely to have hypertension, diabetes, peripheral arterial disease, previous history of CAD including heart attack, PCI, and CABG. Many of the patients in the "no option" group had more than one reason for no further revascularization including chronic total occlusions (70%), diffuse disease (46%), and collateral dependent perfusion (42%). The "no-option" patients had an annual mortality of 3-5%, similar to patients with incomplete revascularization. Researchers speculate the reasons for improved morality could be associated with advances in medical therapy for patients with CAD.

Coronary artery disease is caused by a buildup of plaque (cholesterol deposits) in the arteries supplying blood to the heart. Overtime, plaque buildup can lead to angina (pectoris), a common symptom of CAD that causes severe chest pain due to the inadequate supply of oxygenated blood to the heart. Experts estimate that 16.8 million Americans are living with CAD and 9.8 million have angina. "This growing patient population is in need of novel therapeutic strategies aimed at improving not only mortality but also quality of life," Dr. Henry concluded.


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Woman with MS Summits Everest and Completes the Seven Summits
2. Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate
3. Phybridge Inc. Joins the Cisco Developer Network and Completes Cisco Interoperability Verification Testing
4. The European Medicines Agency Completes Validation Stage for InterMunes Marketing Authorization Application for pirfenidone
5. Pelosi: Today, We Have the Opportunity to Complete the Great Unfinished Business of Our Society and Pass Health Insurance Reform for All Americans
6. SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less?
7. International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc.
8. Anthera Pharmaceuticals Completes Initial Public Offering
9. Kaiser Permanente Completes Electronic Health Record Implementation
10. Solta Medical Completes Acquisition of Aesthera Corporation
11. Neovasc Completes Final Tranche of $1.537 Million Non-Brokered Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be ... groin injury, it occurs when the muscles around the pelvis become inflamed. Over ... the lower torso, as well as accompanying tenderness and weakness. Without proper intervention, ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare and ... hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide ... and value analysis professionals have a ‘seat at the table’ with clinical committees ...
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. Angel ... of a months-long rebranding effort. This includes the introduction of new packaging and ... and market research, we learned that a simple, proactive approach to wellness is ...
(Date:3/27/2017)... ... March 27, 2017 , ... Harris Communications, Inc., a leading provider ... its latest products to the Deaf Seniors of America Conference, April 4-7 at the ... meet with knowledgeable ASL friendly staff from Harris Communications and to try out the ...
(Date:3/24/2017)... ... 2017 , ... Vighter established its NAEMT Authorized Training Center ... Trauma Life Support (PHTLS) course scholarships to four medics assigned to the Minnesota ... cooperation with the American College of Surgeons to promote critical thinking in addressing ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
(Date:3/27/2017)... 2017  PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical ... diseases in children, today reported financial results for ... 31, 2016 and provided an update on its ... make progress during the fourth quarter of 2016 ... primate safety study, and with our lead development ...
(Date:3/24/2017)... Research and Markets has announced the ... report to their offering. ... The Cell Therapy Manufacturing Market, 2017-2027 report ... cell therapy manufacturing and focuses both on contract manufacturers and ... anticipated to emerge as viable alternatives to conventional treatment options. ...
Breaking Medicine Technology: